India carries the highest burden of TB with about 2.69 mn cases in
2018. About 40% of the country's population is estimated to have
latent TB infection. The waiver granted to Sanofi's rifapentine, which
is sold under the brand Priftin, is in the public interest, with a
restricted marketing licence to supply the drug only for the
government-run national TB programme.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/regulator-waives-off-clinical-trials-clears-sanofi-tb-drug/articleshow/71886016.cms
No comments:
Post a Comment